Publicaciones en colaboración con investigadores/as de Complexo Hospitalario Universitario de Santiago (17)

2023

  1. Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7)

    Nature Medicine

2022

  1. Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study

    Clinical Genitourinary Cancer, Vol. 20, Núm. 1, pp. 25-34

  2. Exploring the synergistic effects of cabozantinib and a programmed cell death protein 1 inhibitor in metastatic renal cell carcinoma with machine learning

    Oncotarget, Vol. 13, pp. 237-256

  3. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder

    European Urology, Vol. 82, Núm. 2, pp. 212-222

2021

  1. Circulating levels of the interferon-γ-regulated chemokines cxcl10/cxcl11, il-6 and hgf predict outcome in metastatic renal cell carcinoma patients treated with antiangiogenic therapy

    Cancers, Vol. 13, Núm. 11

  2. Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial

    European urology oncology, Vol. 4, Núm. 3, pp. 456-463

2020

  1. Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7)

    Nature Medicine

  2. The value of pd-l1 expression as predictive biomarker in metastatic renal cell carcinoma patients: A meta-analysis of randomized clinical trials

    Cancers, Vol. 12, Núm. 7, pp. 1-16

2019

  1. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

    Nature Medicine, Vol. 25, Núm. 11, pp. 1706-1714

2018

  1. Radium-223 international early access program: Results from the Spanish subset

    Future Oncology, Vol. 14, Núm. 1, pp. 41-50

2017

  1. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial

    The Lancet Oncology, Vol. 18, Núm. 5, pp. 672-681

  2. Opposing roles of PIK3CA gene alterations to EZH2 signaling in non-muscle invasive bladder cancer

    Oncotarget, Vol. 8, Núm. 6, pp. 10531-10542

  3. Weekly cabazitaxel plus prednisone is effective and less toxic for ‘unfit’ metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial

    European Journal of Cancer, Vol. 87, pp. 30-37

2016

  1. Phase II study of weekly cabazitaxel for ‘unfit’ metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment. Circulating tumour cell (CTC) analysis (SOGUG-CABASEM Trial)

    Annals of Oncology, Vol. 27, pp. vi255

  2. Randomized placebo controlled phase II trial (MAJA): Efficacy results of maintenance vinflunine after cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC). SOGUG 2011-02

    Annals of Oncology, Vol. 27, pp. vi277

2010

  1. Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: Focus on special populations

    Cancer and Metastasis Reviews, Vol. 29, Núm. SUPPL. 1

  2. Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma

    Cancer and Metastasis Reviews, Vol. 29, Núm. SUPPL. 1